Literature DB >> 22462745

Company profile: Sequenom, Inc.

Charles R Cantor1.   

Abstract

There is broad acceptance in both the research and clinical communities that the age of personalized medicine is rapidly approaching. Numerous examples of biomarkers (and tests based on those biomarkers) have been shown to be relevant to clinically important phenotypes. Sequenom, Inc. is at the forefront of this molecular medicine revolution. The company provides genetic analysis instrumentation and reagents to the clinical and research communities. These products are being used for clinical validation of relevant biomarkers as well as for development of diagnostic tests based on those biomarkers.

Mesh:

Substances:

Year:  2012        PMID: 22462745     DOI: 10.2217/pgs.12.8

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  1 in total

Review 1.  The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.

Authors:  P H O'Donnell; A Bush; J Spitz; K Danahey; D Saner; S Das; N J Cox; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2012-08-29       Impact factor: 6.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.